Cabaletta Bio rises on FDA nod for human trials of lupus treatment

Cabaletta Bio

31/03/2023 13:31

** Shares of autoimmune disease drug developer Cabaletta Bio
Inc  CABA.O  rise 7.61% to $7.64 premarket
    ** Co says U.S. FDA has cleared its application to start
trials in humans for CABA-201, treatment for a type of lupus
    ** Plans to initiate early-to-mid-stage CABA-201 trial     
    ** Systemic lupus erythematosus is an autoimmune disease in
which the immune system attacks its own tissues, causing
inflammation and tissue damage
    ** As of last close, stock down ~23%

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))